CG
CBIO

Cutler Group’s Crescent Biopharma CBIO Stock Holding History

Cutler Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4
Closed -$1K – 4237
2019
Q4 		$1K Buy
+4
New +$2.17K ﹤0.01% 3663
2019
Q3 		– Sell
-10
Closed -$2K – 4292
2019
Q2 		$2K Sell
10
-30
-75% -$35.9K ﹤0.01% 3555
2019
Q1 		$3K Buy
+40
New +$45.8K ﹤0.01% 3191
2018
Q4 		– Sell
-90
Closed -$10K – 4166
2018
Q3 		$10K Buy
90
+40
+80% +$60.5K ﹤0.01% 2649
2018
Q2 		$2K Sell
50
-191
-79% -$328K ﹤0.01% 3565
2018
Q1 		$19K Sell
241
-35
-13% -$72.8K ﹤0.01% 2328
2017
Q4 		$121K Buy
+276
New +$365K 0.01% 1260

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cutler Group's CBIO Position: Q4 2019 in Review

Cutler Group sold out of Crescent Biopharma (CBIO) in Q4 2019, closing a stake of 10 shares — an estimated $5.41K sold.

Cutler Group first reported a position in CBIO in Q2 2017 and held it in 8 quarters. The position peaked at $69K in Q2 2018. 78 funds tracked by Wall St. Rank hold CBIO as of Q4 2019.

  • Cutler Group reported no remaining Crescent Biopharma position as of Q4 2019 after selling out during the quarter.
  • Cutler Group sold 10 Crescent Biopharma shares in Q4 2019, an estimated $5.41K.
  • Cutler Group first reported a position in Crescent Biopharma in Q2 2017 and held it in 8 quarters.
  • Cutler Group's Crescent Biopharma position peaked at $69K in Q2 2018.
  • 78 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2019.

Based on Cutler Group's 13F filing for Q4 2019, filed 6 Feb 2020.